Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective
Jeremy Yuen‐Chun Teoh(Chinese University of Hong Kong), Marek Babjuk(Charles University), Petros Grivas(Seattle Cancer Care Alliance), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Peter C. Black(University of British Columbia), Shahrokh F. Shariat(Universitätszahnklinik Wien)
Cited by 196
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k